Methylthiouracil

Methylthiouracil is an antithyroid agent. Methylthiouracil suppresses the production TNF-α and IL-6, and the activation of NF-κB and ERK1/2.

Product Specifications

CAS Number

[56-04-2]

Product Name Alternative

MTU

UNSPSC

12352005

Hazard Statement

H317, H351, H401

Target

ERK; Interleukin Related; NF-κB; TNF Receptor

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; NF-κB; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/methylthiouracil.html

Concentration

10mM

Purity

99.93

Solubility

DMSO : ≥ 50 mg/mL

Smiles

O=C(C=C(C)N1)NC1=S

Molecular Formula

C5H6N2OS

Molecular Weight

142.18

Precautions

H317, H351, H401

References & Citations

[1]Ku SK, et al. Anti-inflammatory effects of methylthiouracil in vitro and in vivo. Toxicol Appl Pharmacol. 2015 Nov 1;288 (3) :374-86.|[2]Heeremans A, et al. Elimination profile of methylthiouracil in cows after oral administration. Analyst. 1998 Dec;123 (12) :2629-32.|[3]EAYRS JT, et al. The effect of thyroid deficiency induced by methyl thiouracil on the maturation of the central nervous system. J Anat. 1951 Oct;85 (4) :350-8.|[4]Coda AR, et al. In vivo imaging of CNS microglial activation/macrophage infiltration with combined [18F]DPA-714-PET and SPIO-MRI in a mouse model of relapsing remitting experimental autoimmune encephalomyelitis. Eur J Nucl Med Mol Imaging. 2021 Jan;48 (1) :40-52.|[5]Hofstetter HH, et al. Kinetics and organ distribution of IL-17-producing CD4 cells in proteolipid protein 139-151 peptide-induced experimental autoimmune encephalomyelitis of SJL mice. J Immunol. 2007 Feb 1;178 (3) :1372-8.